Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer

Veronica Rendo1,2, Snehangshu Kundu1, Natallia Rameika2, Viktor Ljungström1, Richard Svensson3,4, Kimmo Palin5,6, Lauri Aaltonen5,6, Ivaylo Stoimenov1,7 & Tobias Sjöblom1,7*

Therapies targeting somatic bystander genetic events represent a new avenue for cancer treatment. We recently identified a subset of colorectal cancer (CRC) patients who are heterozygous for a wild-type and a low activity allele (NAT2*6) but lack the wild-type allele in their tumors due to loss of heterozygosity (LOH) at 8p22. These tumors were sensitive to treatment with a cytotoxic substrate of NAT2 (6-(4-aminophenyl)-N-(3,4,5-trimethoxyphenyl)pyrazin-2-amine, APA), and pointed to NAT2 loss being a therapeutically exploitable vulnerability of CRC tumors. To better estimate the total number of treatable CRC patients, we here determined whether tumor cells retaining also other NAT2 low activity variants after LOH respond to APA treatment. The prevalent low activity alleles NAT2*5 and NAT2*14, but not NAT2*7, were found to be low metabolizers with high sensitivity to APA. By analysis of two different CRC patient cohorts, we detected heterozygosity for NAT2 alleles targetable by APA, along with allelic imbalances pointing to LOH, in ~24% of tumors. Finally, to haplotype the NAT2 locus in tumor and patient-matched normal samples in a clinical setting, we develop and demonstrate a long-read sequencing based assay. In total, >79,000 CRC patients per year fulfill genetic criteria for high sensitivity to a NAT2 LOH therapy and their eligibility can be assessed by clinical sequencing.

Colorectal cancer (CRC) is the third most common form of cancer in the world with more than 1.4 million newly diagnosed cases and almost 700,000 deaths in 2012. Surgery followed by conventional chemotherapy remains the preferred treatment of CRC. Although several targeted therapies are used in the clinical management of unresectable CRCs, the development of novel therapeutic avenues is warranted because of resistance development. Several recent strategies seek to target somatic loss of bystander genes located near tumor suppressor genes for cancer therapy. We recently reported that LOH at the NAT2 locus on 8p22 can be exploited for therapy using APA, a cytotoxic low molecular weight compound. The NAT2 gene encodes N-acetyltransferase 2, a cytosolic enzyme involved in phase II metabolism of xenobiotics, which is highly polymorphic and has >100 known single nucleotide variants (SNVs) in the protein coding sequence. The majority of these variants give rise to protein products with lower acetylator activity than the wild-type allele. The expression of NAT2 is largely confined to epithelial cells of the gastrointestinal tract and liver, but NAT2 protein has also been detected in lung, bladder and other tissues exposed to xenogenous compounds. Due to chromosome arm LOH at 8p22 during the early development of CRC, a patient heterozygous for a rapid and a slow NAT2 allele may lose the rapid variant in the tumor cells, effectively rendering them deficient in NAT2 activity and sensitive to a cytotoxic substrate of NAT2. As the normal epithelial cells of gut and liver express also the wild-type NAT2 allele, they can evade APA toxicity. The number of patients standing to benefit from treatment with APA will depend on (1) the fraction of...
the CRC patient population that has a targetable NAT2 intermediate acetylator phenotype (i.e. harbor a rapid and a slow NAT2 allele where the slow allele cannot process APA), and (2) the fraction of CRCs that lose their rapid NAT2 allele. It is therefore essential to understand which specific slow NAT2 alleles confer sensitivity to APA and to determine their prevalence in CRC patient populations in order to advance to clinical implementation.

The distribution of NAT2 alleles differs in populations from geographically separated regions, but combinations of alleles encoding intermediate or low NAT2 enzymatic function are present in all\(^15\). For example, the wild type allele NAT2*4 and the alleles NAT2*11, NAT2*12, NAT2*13 encode proteins with a rapid acetylator phenotype, whereas the allele groups NAT2*5, NAT2*6, NAT2*7 and NAT2*14 confer the slow acetylator phenotype\(^16,17\). We focused our previous studies\(^11\) on tumor cells expressing the wild-type NAT2*4 (rapid) or the NAT2*6 (slow) acetylator allele, and it is currently unknown which, if any, alleles arising from the compendium of NAT2 slow acetylator variants that can be exploited in LOH-based therapy using APA. Once these variants are identified, accurate haplotype resolution at the NAT2 locus of normal and tumor samples is required for diagnostic purposes. Sanger sequencing and single nucleotide polymorphism (SNP) arrays are limited with respect to haplotype resolution as they rely on statistical inference to resolve complex genotype data\(^19\). More recently, haplotype phasing of high-throughput short-read next-generation sequencing (NGS) data has been employed, but this method heavily relies on high density of SNPs for accurate inference\(^19\). As sequencing methods based on single-molecule real-time (SMRT) sequencing can provide more reliable resolution of alleles and haplotypes at a comparable cost per sample\(^20,21\), we hypothesize that the implementation of these long-read based assays will improve the resolution of NAT2 haplotypes.

In the present study, we seek to determine the number of patients who can benefit from a cytotoxic compound (APA) targeting LOH of NAT2 (Fig. 1). First, we construct CRC cell model systems to assess the applicability of APA treatment in cases where the tumor is left with the slow NAT2 alleles belonging to the groups NAT2*5, NAT2*7 and NAT2*14. Next, we genotype NAT2 in two independent CRC patient cohorts to determine frequencies of alleles and LOH events. For diagnostic purposes, we finally develop a low-cost long-read sequencing protocol for the multiplexed NAT2 haplotyping of patient-matched normal and tumor samples.
Results

Analysis of NAT2 slow acetylator allele prevalence and estimation of patients eligible for allele selective therapy. We determined the NAT2 allele group frequencies from the phased haplotypes of 2054 individuals sequenced by the 1000 Genomes Project \(^22\) and observed that the slow acetylator alleles from the groups NAT2*5, NAT2*6, NAT2*4 and NAT2*14 represented 29.3%, 26.5%, 7.7% and 2.8% of the total alleles, respectively. The fraction of heterozygous individuals with the slow acetylator variants *5 (rs1801280), *6 (rs1799931), *7 (rs72554617) and *14 (rs1801279) were 35.7%, 36.7%, 13.0% and 5.0%, respectively. However, only heterozygous individuals with one slow and one rapid acetylator allele (NAT2*4 or NAT2*12) are considered for allele-selective therapy. Heterozygosity was present in 15.1% (NAT2*5/Rapid), 13.4% (NAT2*6/Rapid), 5.7% (NAT2*7/Rapid) and 1.6% (NAT2*14/Rapid) of samples. We detected only one allele from the group NAT2*10 and no other slow acetylator alleles in the dataset. The data suggest that ~ 35.8% of the global population has an intermediate NAT2 acetylator phenotype through heterozygosity of prevalent rapid and slow NAT2 alleles. Given that ~ 21% of colorectal tumors undergo LOH at 8p22 \(^23\), we estimate that ~ 79,000 individuals heterozygous for a NAT2 slow allele could potentially be eligible for therapy every year (given an annual incidence of 1.3 million CRC cases) (Supplementary Table 1). We previously demonstrated that cells encoding the NAT2*6 variant are more sensitive to APA treatment than those expressing a NAT2*4 rapid acetylator allele \(^1\). The observation that there are almost twice as many intermediate acetylators carrying a slow allele from the groups NAT2*5, NAT2*7 and NAT2*14 as compared to NAT2*6 motivated further functional studies to determine the response of these alternative slow acetylator alleles to APA.

Prediction of NAT2 haplotypes and LOH events in two independent CRC patient cohorts. We next sought to identify the frequencies at which the different NAT2 slow variants are present in two independent cohorts of CRC patients. We first genotyped a Finnish cohort of 1611 CRC patients \(^24\) by querying 7 common allele-classifying NAT2 SNPs and 11 additional variants in tumor and patient-matched normal samples. We were able to derive the haplotypes of 1,511 individuals, identifying the allele group NAT2*5 (45.9%) as the most frequent followed by *4 (26.5%), *6 (23.5%), *7 (4.1%) and *12 (< 0.1%) (Fig. 2A). Heterozygous individuals carrying a wild-type NAT2*4 allele and a slow acetylator *5A, *5B, *5C, *6A or *7B allele constituted 37.3% of the CRC patients. Next, we determined the fraction of tumors retaining a slow NAT2 acetylator allele after undergoing LOH in chromosome 8p22. Allelic imbalance was observed in 30.9% of all predicted intermediate acetylators, and the wild-type allele was lost in 52.9% of the putative LOH events (Table 1). Considering all tumors, the LOH frequency at the NAT2 locus in all tumors was 24.3%. We then studied a cohort of 56 Swedish patients by analysis of tumor and patient-matched normal samples whole genome sequenced at a read depth of 90 ×. By calling 14 SNP positions in the NAT2 locus, we were able to define tumor and normal haplotypes in each patient and identify allele losses occurring in the former. The highest allele frequency was present in groups NAT2*5 (44.6%) and *6 (31.3%), followed by NAT2*4 (19.6%) and NAT2*7 (4.5%) (Fig. 2B). For two patients, haplotypes could not be assigned due to a low number of sequencing reads and uncertain base calling. One-quarter (26%) of patients were heterozygous intermediate acetylators carrying NAT2*4/6A or *4/5B, and 3 additional intermediate acetylator individuals (5%) had *4/5A, *4/5C or *4/7B genotypes. Again, LOH events were detected in 19.6% of the total cohort and particularly in 40% of heterozygous patients with the NAT2*4/*5B haplotype. Analyses
of these two cohorts revealed five different NAT2 genotypes in heterozygous patients losing wild-type NAT2 in their tumors (Table 1) and motivated further understanding on whether CRC patients with the NAT2*4/5B or *4/7B haplotypes are also eligible for LOH-based therapy. We did not detect any individual heterozygous for the NAT2*14 slow acetylator allele but included this variant in downstream analyses as tumors retaining the slow allele may also show susceptibility to NAT2 allele-selective compounds.

**Table 1.** Distribution of NAT2 genotypes and LOH events identified in tumor/normal colorectal cancer pairs in (1) Finnish cohort, (2) Swedish cohort and (3) combined data. NAT2 acetylator phenotype was called based on rs1801279, rs1041983, rs1801280, rs1799929, rs144176822, rs1799930, rs1208, rs1799931, rs2552, rs4646247, rs971473, rs45547533, rs721398 and rs721399 genotypes. Terms in bold refer to the acetylator phenotype of each tumor (rapid, intermediate or slow) given its NAT2 haplotype.

| NAT2 haplotype | Number of individuals | LOH events in intermediate acetylators | Cases where the *4 allele is lost |
|----------------|-----------------------|----------------------------------------|----------------------------------|
|                | (1)                  | (2)                    | (3)                   | (1)                   | (2)                   | (3)                   |
| **Rapid acetylators** |                             |                         |                        |                          |                        |                        |
| NAT2*4/*4       | 117                  | 119                    | 1                     | 0                     | 1                     | 0                     |
| NAT2*4/*12A    | 2                    | 2                     | 2                     | 0                    | 2                     | 0                     |
| Total          | 119                  | 121                    | 3                     | 0                     | 3                     | 2                     |
| **Intermediate acetylators** |                             |                         |                        |                          |                        |                        |
| NAT2*4/*5A     | 20                   | 21                    | 4                     | 0                     | 4                     | 2                     |
| NAT2*4/*5B     | 328                  | 338                   | 95                    | 4                     | 99                    | 50                    |
| NAT2*4/*5C     | 16                   | 17                    | 6                     | 1                     | 7                     | 3                     |
| NAT2*4/*6A     | 170                  | 175                   | 58                    | 0                     | 58                    | 29                    |
| NAT2*4/*7B     | 30                   | 31                    | 11                    | 0                     | 11                    | 8                     |
| Total          | 564                  | 582                   | 174                   | 5                     | 179                   | 92                    |
| **Slow acetylators** |                             |                         |                        |                          |                        |                        |
| NAT2*5A/*5A    | 1                    | 0                     | 0                     | 0                     | 0                     | 0                     |
| NAT2*5B/*5B    | 228                  | 234                   | 12                    | 0                     | 12                    | 0                     |
| NAT2*5C/*5C    | 3                    | 3                     | 0                     | 0                     | 0                     | 0                     |
| NAT2*5A/*5B    | 33                   | 33                    | 15                    | 0                     | 15                    | 0                     |
| NAT2*5A/*5C    | 6                    | 6                     | 3                     | 0                     | 3                     | 0                     |
| NAT2*5B/*5C    | 35                   | 38                    | 16                    | 0                     | 16                    | 0                     |
| NAT2*5A/*6A    | 20                   | 21                    | 6                     | 0                     | 6                     | 0                     |
| NAT2*5B/*6A    | 308                  | 326                   | 106                   | 0                     | 106                   | 0                     |
| NAT2*5C/*6A    | 19                   | 19                    | 5                     | 0                     | 5                     | 0                     |
| NAT2*5A/*7B    | 5                    | 5                     | 2                     | 0                     | 2                     | 0                     |
| NAT2*5B/*7B    | 58                   | 61                    | 15                    | 0                     | 15                    | 0                     |
| NAT2*5C/*7B    | 1                    | 1                     | 1                     | 0                     | 1                     | 0                     |
| NAT2*6A/*6A    | 84                   | 88                    | 0                     | 0                     | 0                     | 0                     |
| NAT2*6A/*7B    | 25                   | 26                    | 9                     | 0                     | 9                     | 0                     |
| NAT2*7B/*7B    | 2                    | 2                     | 0                     | 0                     | 0                     | 0                     |
| Total          | 828                  | 864                   | 190                   | 0                     | 190                   | 0                     |
| Total patients | 1511                 | 1567                  | 1567                  | 372                   | 90                    | 95                    |

**Generation of CRC cell model systems expressing NAT2 slow acetylator variants.** To determine which of the common slow acetylator NAT2 alleles can be exploited for NAT LOH therapies, we developed cell model systems expressing the slow acetylator variants encoded by the NAT2*5, *7 and *14 allele groups. The CRC cell line RKO was selected as a genetic background due to its lack of endogenous NAT2 expression. A total of 6 stable clones encoding NAT2*5, 5 clones encoding *7 and 4 clones encoding *14 were obtained after transduction and selection of RKO cells (Supplementary Fig. 1). Further RT-qPCR analysis allowed selection of 2 clones with similar mRNA expression levels for each NAT2 slow acetylator variant (Fig. 3A). For the final set of 6 clones, the correct genotype and gene expression of the variants rs1801280 (NAT2*5), rs1799931 (NAT2*7) and rs1801279 (NAT2*14) was confirmed by PCR-coupled Sanger sequencing (Fig. 3B) and immunoblotting (Fig. 3C, D). All 3 slow acetylator variant clones grew at similar rates to parental RKO cells when cultured under normal medium conditions (Supplementary Fig. 2). Taken together, the generated cell systems were considered suitable tools for determination of NAT2 kinetic parameters and sensitivity towards agents targeting LOH.

**Quantification of NAT2 catalytic activity in slow acetylator variants.** To determine the kinetic parameters underlying acetylation of the NAT2_5, NAT2_7 and NAT2_14 protein variants, cells were treated
with increasing concentrations of the cytotoxic NAT2 substrate APA, a substrate for which a 40-fold increased affinity was observed in rapid NAT2_4 versus slow NAT2_6 CRC cells. Impaired selectivity towards APA was observed in NAT2_5 (Vmax/Km = 0.80 and 0.64 µl/min/10⁶ cells) and NAT2_14 variants (Vmax/Km = 0.03 and 0.38 µl/min/10⁶ cells), leading to >20 and >100-fold less efficient NAPA formation as compared to the wild-type NAT2 clone (Vmax/Km = 15.5 µl/min/10⁶ cells) (Fig. 4A, C). Interestingly, clones expressing the NAT2_7 variant (Vmax/Km = 11.8 and 5.0 µl/min/10⁶ cells) showed much higher acetylation efficiency, comparable to the wild-type enzyme and one clone also displaying substrate inhibition kinetics (Fig. 4B). The low levels of NAT2 catalytic activity observed in the NAT2_5 and NAT2_14 variants are in agreement with the kinetic profile obtained for NAT2_6-mediated APA acetylation and suggest that tumor cells retaining these variants after undergoing LOH would have comparable sensitivity levels towards APA treatment.

**Figure 3.** Generation of stable CRC cell clones expressing NAT2 slow acetylator variants. (A) Two clones encoding each of the indicated NAT2 slow acetylator variants were chosen for downstream analyses based on their expression of NAT2 RNA relative to parental RKO cells. Data from one representative experiment shown. (B) Sanger sequencing revealed the correct 341 T > C, 857 G > A, and 191 G > A substitutions in the NAT2 coding region (black arrows) to generate the NAT2*5, *7, and *14 alleles. (C) Protein expression of NAT2 slow acetylator variants by immunoblotting. A Myc-tag antibody was used to detect recombinant NAT2 with β-actin as loading control. Full-length immunoblots are presented in Supplementary Fig. 4. (D) Quantification of immunoblots shown in (C). Protein expression levels were normalized against β-actin.

**Sensitivity of NAT2 slow acetylator variants towards APA treatment.** The low molecular weight compound APA shows selective toxicity towards cells expressing the slow acetylator NAT2_6 protein. To investigate whether this sensitivity extends to the remaining NAT2 slow acetylator variants, a full dose–response for APA was determined in cells expressing NAT2_5, -_7 and -_14. Cells expressing the NAT2_5 (IC₅₀ = 0.86 µM)
and NAT2_14 (IC50 = 0.15 µM) slow acetylator variants showed a > fourfold decrease in viability when compared to wild-type NAT2 (Fig. 4D, F). In contrast, NAT2_7-expressing clones had cell viability rates (IC50 = 3.46 µM) comparable to wild-type cells (Fig. 4E). To confirm that the observed APA response was dependent on NAT2, we performed a similar dose–response curve with fluorouracil (5-FU), a standard CRC chemotherapy drug which is not metabolized by NAT2. The cell viability of all clones was equally impaired by 5-FU in all assessed NAT2 genotypes (Supplementary Fig. 3). Taken together, we conclude that NAT2*5 and NAT2*14, but not NAT2*7 slow acetylator alleles, encode variants sensitive to APA treatment.

**NAT2 haplotype resolution by multiplex SMRT sequencing.** The resolution of NAT2 haplotypes is critical for understanding whether a colorectal tumor has undergone LOH and is eligible for APA treatment. However, conventional Sanger sequencing as well as short read sequencing methods are not able to discern whether polymorphisms are present in the same allele or in different alleles of the NAT2 gene, thereby impairing the understanding of which specific allele has been lost in tumor cells. Indeed, Sanger sequencing was able to resolve the polymorphisms in the CRC cell lines RKO, DLD-1, and VaCo-703 which are homozygous for all NAT2 polymorphisms, but not in HepG2 cells where heterozygosity was observed at all 7 polymorphic sites (Fig. 5A). To create a clinically useful multiplexed method for NAT2 haplotyping, we turned to long-read SMRT sequencing technology, which assigns each NAT2 polymorphism to a particular DNA strand and allows for the complete resolution of allele groups in a sample. Targeted enrichment of NAT2 was performed in several samples at the same time, allowing for the quantification and pooling of the resulting PCR products for multiplexed SMRT sequencing (Fig. 5B). First, a 2096 bp long-range PCR product encompassing the entire protein-encoding sequence (exon 2) of NAT2 was amplified from genomic DNA of RKO, DLD-1, VaCo-703 and HepG2 cell lines and analyzed by PacBio sequencing. Two independent and separately labeled PCR products were obtained for each of the cell lines (Fig. 5C; Supplementary Table 2). Four amplicons (one for each cell line) were mixed in equimolar ratio (Pool A) and the other four pooled according to a concentration estimate based on qPCR data (Pool B). The pools were mixed at equimolar ratio and subjected to multiplex

**Figure 4.** Colorectal cancer cells expressing NAT2_5 and NAT2_14 but not NAT2_7 are sensitive to APA treatment. (A–C) Quantification of NAT2 catalytic activity in RKO clones expressing (A) NAT2_5, (B) NAT2_7 and (C) NAT2_14 enzymatic variants. The velocity at which APA becomes acetylated was measured by LC–MS/MS at different concentrations. A representative experiment is shown for each enzymatic variant. (D–F) Dose response for APA in RKO clones expressing the (D) NAT2_5, (E) NAT2_7 and (F) NAT2_14 enzymatic variants. Cell viability was measured by a MTT assay after 72 h. The mean and S.D. of three independent experiments is shown. Data were analyzed using a two-way ANOVA. **p < 0.01 and ****p < 0.0001.
Figure 5. NAT2 haplotype resolution by multiplex SMRT sequencing. (A) Sanger sequencing does not allow the resolution of NAT2 haplotypes in samples that are polymorphic in more than one position. The genotype of HepG2 cells is shown for each of the seven standard positions used for NAT2 allele calling. (B) Workflow for multiplexed SMRT sequencing. Genomic DNA was extracted from the cancer cell lines to be haplotyped. The NAT2 region is amplified in each sample by using primer pairs with a unique barcode and a padding sequence. The resulting PCR products were quantified by Qubit measurements or qPCR analysis and pooled in equimolar ratios for multiplexed SMRT sequencing. (C) Barcoded PCR products resulting from NAT2 amplification in RKO, DLD-1, VaCo-703 and HepG2 cell lines with two different sets of primers. Samples were run in a 1.5% agarose gel and water was used as a negative PCR control. Full-length gels are presented in Supplementary Fig. 4. (D) Visualization of the individual alleles present in RKO, DLD-1, VaCo-703 and HepG2 cell lines in Integrative Genomics Viewer. De-multiplexed SMRT sequencing reads from each cell line are aligned to the NAT2 reference sequence. Selection of reads in both positive (red) and negative (blue) direction supporting the NAT2*6A allele in RKO, DLD1, VaCo-703, HepG2 and NAT2*5B allele in HepG2 are shown. The gray stacks above each alignment represent the sequencing coverage. Vertical colored lines illustrate the positions of variation from the reference.
sequencing in a single SMRT cell. For the 8 amplicons, we obtained 53,828 reads of the insert with a mean length of 1715 nt and mean quality of 97.32% following 10 sequence passes on average. We based the analysis on sequencing reads with lengths 1500 nt to 2300 nt where the barcode was successfully identified, resulting in 33,817 reads (62.8% of total). Following barcode trimming and read alignment, 99.8% of the sequencing reads aligned to the NAT2 locus. For the samples from Pool A, the number of aligned reads was 3913 ± 235 (mean and SD), compared to 4540 ± 749 for Pool B. While the amplicon mean coverage was comparable, a larger standard deviation was observed in Pool B. While RKO, DLD-1 and VaCo-703 cells were homozygous in the sequenced region and carried the NAT2*6A allele as suggested by Sanger sequencing, HepG2 cells were polymorphic in 7 sites and the haplotype calling from long-read sequencing revealed the NAT2 slow-acetylator alleles NAT2*6A and NAT2*5B (Fig. 5D). Taken together, these results demonstrate SMRT sequencing as a valid haplotyping tool to predict NAT2 acetylator phenotypes in cancer patients and their tumors.

**NAT2 acetylator phenotype prediction by SMRT sequencing of tumor-normal pairs.** After confirming that NAT2 haplotype resolution is feasible by SMRT sequencing, we aimed to resolve the genotype of 74 CRC tumor and patient-matched normal tissues, which included the Swedish cohort. We sequenced the barcoded NAT2 amplicons from the normal tissues in two separate SMRT cells with 37 samples each, whereas the patient-matched tumor samples were sequenced in three additional SMRT cells with ~25 samples each, aiming for better tumor coverage. Following removal of short sequencing reads (<1500 nt), barcode de-multiplexing and read alignment we observed that mean NAT2 coverage per sample was 1547× in the normal tissues and 2229× for the tumor samples, which was deemed sufficient to call the haplotypes. We called the haplotypes from the reads covering all 7 allele-classifying polymorphic sites (rs1801279, rs1041983, rs1801280, rs17999929, rs1799930, rs1208, rs1799931) (Supplementary Table 3). Sample N_ID:128 was covered by 175 reads, from which 147 reads span all 7 polymorphic sites and was called as homozygous for the NAT2*5B allele. In the corresponding tumor sample (T_ID:127) the increase of coverage to 2235× did not reveal a second allele. In sample N_ID:148 with similarly low coverage (238×), two alleles were resolved (NAT2*5B/*6A). The allele groups NAT2*4/*5B/*6A and NAT2*5B/*6A were detected in 22.3% and 50.7% of the patients, respectively. The data from the complete NAT2 haplotypes implied that 25 individuals (33.8%) were intermediate acetylators consistent with the genotypes and imputed haplotype data from the SNP arrays and NGS sequenced cohorts. We detected LOH of NAT2 in 19 tumor samples (25.7%) of which 13 were from individuals with an intermediate acetylator phenotype. The LOH events in the intermediate acetylators indicated that the wild-type allele was lost in 3 cases (4% of total). The long-read sequencing approach additionally identified a novel wild-type NAT2*/4 allele with a rare synonymous SNP (rs144176822). We conclude that SMRT sequencing enables NAT2 haplotype resolution for multiple samples by analyzing sequencing reads spanning the NAT2 gene.

**Discussion**

The vast majority of human cancers exhibit genomic instability at the chromosomal level. Such cancers acquire somatic changes in chromosomal number and structure throughout tumor progression. Cancer vulnerabilities emerging from these genomic losses have been proposed as promising putative targets for the selective treatment of solid tumors. Examples include the loss of bystander metabolic enzymes lost in conjunction with tumor suppressor genes, enabling inhibition by collateral lethality. Similarly, loss of essential genes in the spliceosome or proteasome can render cancer cells sensitive to further suppression of these genes. Cancer vulnerabilities reducing the genetic complexity of tumors and have demonstrated that NAT2 could serve as a target in colorectal cancer. We focused on NAT2*6 heterozygous individuals which lose the functional NAT2 allele in their tumors (as 6 is the slow acetylator allele with the highest heterozygous population frequency) and demonstrated that cell lines and tumors expressing the slow acetylator NAT2*6 allele are more sensitive to APA treatment than those expressing a rapid acetylator NAT2 allele. Based on structural similarity with kinase inhibitors, we additionally performed a kinome screen to profile binding of APA and its acetylated product NAPA to AURKA, activation of phospho-AURKA in tumor cells expressing the slow acetylator NAT2*6 allele. We were able to determine binding of APA to AURKA, activation of phospho-AURKA in slow but not rapid acetylator tumor cells, and mitotic arrest along with formation of multipolar mitotic spindles in CRC cells expressing the slow acetylator variant. In this study, we hypothesized that individuals carrying other slow variant alleles may also be eligible for APA treatment. Tumor cells encoding the slow acetylator variants NAT2*5 and *14 indeed responded to APA treatment and had similar kinetic profiles when compared to cells expressing the *6 allele group. This is in concordance with previous analyses of sulfamethazine N-acetylation in human hepatocytes, where NAT2-mediated substrate processing occurs at similar rates for all slow acetylator variants. In contrast, cells encoding the NAT2*7 variant showed higher efficiency of APA acetylation and responses to APA treatment that are comparable to cells expressing wild-type NAT2 activity. We hypothesize that this effect is particular for APA.

Haplotyping of NAT2 in two different colorectal cancer cohorts revealed several combinations of alleles that encode intermediate acetylator phenotypes. For patients heterozygous for NAT2, we observed an almost equal probability of losing either allele after the tumor undergoes LOH. The LOH frequency for the NAT2 locus was > 23% in both cohorts, which is considerably higher than previously reported. This discrepancy could be a result of population specific factors, a difference in the number of patients and most importantly of the amount of SNP variation probed. Besides detecting a loss of the wild type NAT2*4 allele in tumors from NAT2*4/*6A individuals (17%), we observed that the same allele can be lost in the tumors of NAT2*4/*5B (15%) and NAT2*4/*7B (27%) individuals. The largest number of intermediate acetylators in both patient cohorts carried a NAT2*4/*5B genotype and, despite the lower LOH frequency observed in the NAT2*4/*5B genetic background compared to the LOH frequency in NAT2*4/*6A or NAT2*4/*7B backgrounds, the NAT2*4/*5B intermediate acetylators...
contributed with the most cases of potentially eligible patients (3.3% of total haplotyped individuals). All intermediate acetylators in our cohorts which lost a wild-type allele in the tumor, account for ~6% of cases. These results significantly expand the population of patients eligible for LOH therapy and motivate the development of practical diagnostic tools to identify this clinically relevant subset. No carriers of the NAT2*14 slow acetylator allele were identified, presumably because this allele is not present in the studied populations. As NAT2*1A4 or NAT2*14B haplotypes are found in Spanish (0.39%), German (0.13%) and US Caucasian (0.12%) populations, eligible patients could be found in these cohorts. Despite their low frequency, our functional data suggests that tumors encoding the NAT2*14 variant are equally sensitive to APA treatment and should be considered for LOH-base therapy.

Routine identification of NAT2 intermediate acetylators in the clinic requires a practical genotyping tool, able to resolve the haplotypes with high accuracy and allowing for multiplexing. Commonly used methods such as Sanger sequencing and SNP arrays employ statistical inference to resolve haplotypes, which can lead to an ambiguous interpretation of the data. Alternatively, haplotype resolution can be performed from short reads obtained from next-generation sequencing, but the output is highly dependent on the frequency of the polymorphism that needs to be inferred. We developed SMRT sequencing of NAT2 as a practical diagnostic technology, assigning the genetic variation found in the NAT2 locus to each DNA strand of the individual and potentially allowing the identification of LOH events in the patient’s tumor. By using SMRT sequencing, we were able to resolve the different NAT2 alleles present in several cell lines and developed a pipeline for multiplexed analysis. We resolved both NAT2 alleles (N_ID:148, Supplementary Table 2) from as little as 181 sequencing reads spanning the protein-coding part of the gene and observed on average 43,208 such alleles per SMRT cell. This suggests that one SMRT cell can be used to resolve the NAT2 haplotypes of more than 200 samples, provided equimolar DNA pooling and barcode availability. This method can now be used as a tool for haplotyping colorectal cancers and patient-matched normal samples, with the aim of identifying small, hidden, and common genetic variants in tumors, with the potential to discover novel markers of cancer predisposition.

To estimate LOH frequency from patient-matched tumor-normal samples we used three different methods: SNP-array genotyping, whole-genome sequencing and long-read SMRT sequencing. Genomic arrays and next-generation sequencing approaches allow for the detection of modest allelic imbalances in tumor samples, and provide increased resolution capacity for highly polymorphic loci when compared to LOH blots. However, it’s important to note that no sequencing method on its own can report an LOH event with absolute confidence. The major factors for this uncertainty are: (1) variable tumor purity, (2) tumor heterogeneity and clonality of LOH events, and (3) potential allele biases in the library preparation, sequencing and analysis of the samples. From the three implemented methods, the long-read SMRT sequencing can be considered the best haplotyping strategy since the evidence for each allele is direct and based on independently sequenced single molecules covering both directions of the DNA strands. This is clearly demonstrated by the detection of the rare g.18400582G>T polymorphism and its unambiguous assignment to a novel NAT2*4 allele in a NAT2*4/5B genotype context. The drawback of long-read sequencing is in the sample preparation steps, which may be more laborious than SNP array genotyping or whole-genome sequencing. Long-read SMRT sequencing has been previously proposed for haplotyping of highly polymorphic loci, and here we suggest for the first time NAT2 LOH detection as an application. The LOH detection protocol based on long-read sequencing needs further refinement before being accepted as a diagnostic grade protocol, especially given the ambiguity of the allelic imbalance threshold above which one should call an LOH event. However, the long-read sequencing can easily be applied in most clinical laboratories as a low-cost multiplexing method for simultaneous haplotyping of tumor and normal samples, with a possible LOH suggestion in the tumor.

Given the LOH frequencies detected in our studied cohorts, and the response of the different NAT2 slow acetylator variants to APA, we estimate that each year at least 79,000 worldwide CRC patients could benefit from LOH-based targeting. However, the NAT2-allele selective therapy may have broader cancer applicability. In addition to the expression of NAT2 in the tissues of the gastrointestinal tract and liver, detectable protein levels are present in the lung, bladder, ureter and kidneys. Cancers of the liver, lung and kidney are also prone to LOH-base therapy. To estimate LOH frequency from patient-matched tumor-normal samples we used three different methods: SNP-array genotyping, whole-genome sequencing and long-read SMRT sequencing. Genomic arrays and next-generation sequencing approaches allow for the detection of modest allelic imbalances in tumor samples, and provide increased resolution capacity for highly polymorphic loci when compared to LOH blots. However, it’s important to note that no sequencing method on its own can report an LOH event with absolute confidence. The major factors for this uncertainty are: (1) variable tumor purity, (2) tumor heterogeneity and clonality of LOH events, and (3) potential allele biases in the library preparation, sequencing and analysis of the samples. From the three implemented methods, the long-read SMRT sequencing can be considered the best haplotyping strategy since the evidence for each allele is direct and based on independently sequenced single molecules covering both directions of the DNA strands. This is clearly demonstrated by the detection of the rare g.18400582G>T polymorphism and its unambiguous assignment to a novel NAT2*4 allele in a NAT2*4/5B genotype context. The drawback of long-read sequencing is in the sample preparation steps, which may be more laborious than SNP array genotyping or whole-genome sequencing. Long-read SMRT sequencing has been previously proposed for haplotyping of highly polymorphic loci, and here we suggest for the first time NAT2 LOH detection as an application. The LOH detection protocol based on long-read sequencing needs further refinement before being accepted as a diagnostic grade protocol, especially given the ambiguity of the allelic imbalance threshold above which one should call an LOH event. However, the long-read sequencing can easily be applied in most clinical laboratories as a low-cost multiplexing method for simultaneous haplotyping of tumor and normal samples, with a possible LOH suggestion in the tumor.

Methods
Ethical permits. Sequence analyses of patient samples were performed under ethical permits from EPN Uppsala (2007:116) and the Ethics Committee of the Hospital District of Helsinki and Uusimaa following participant informed consent. Signed informed consent or authorization from the National Supervisory Authority for Welfare and Health has been obtained for all Finnish sample materials used. All analyses were performed in accordance with relevant guidelines and regulations.

Generation of stable clones with ectopic expression of slow NAT2 variants. The human colorectal cancer cell line RKO (ATCC) was maintained in McCoy’s 5A medium supplemented with 10% Fetal Bovine Serum and 1% Pen Strep (Life Technologies). Lentiviral particles encoding NAT2*5, NAT2*7 and NAT2*14 slow acetylator variants within the Lv125C backbone sequence were acquired from LabOomics. The day before transduction, 50,000 cells were plated in a 24-well plate. Viruses were diluted in 250 µL of normal growth medium containing 7.5 mg/mL sequa-brene (Sigma) and added to each well. After 24 h of incubation at 37 °C, the virus-containing medium was replaced with fresh normal growth medium. After 48 h, transduced cells were selected with 1 µg/mL puromycin (Thermo Fisher Scientific) for 10 days. Next, 3 cell pools of each NAT2 slow acetylator
variant were subjected to single clone selection and screening. To confirm the genotype of each clone, genomic DNA was isolated following a standard protocol for cultured cells (Macherey–Nagel) and amplification of the lentiviral NAT2 insert was performed by PCR with the forward primer 5′-GGGTAAGGCTGTTGAGGTT-3′ and reverse primer 5′-TTGGTGCAGATCTCTGC-3′. Each reaction contained 1× Phusion HF Buffer (Thermo Scientific), 0.2 mM dNTPs, 0.2 μM forward and reverse primers, 0.02 U/μL Phusion DNA Polymerase (Thermo Scientific) and 6 ng of genomic DNA. The PCR was performed in a 2720 Thermal Cycler (Applied Biosystems) and consisted of 1 cycle of 98 °C for 30 s and 30 cycles of 98 °C for 10 s, 61 °C for 15 s and 72 °C for 20 s followed by 1 cycle of 72 °C for 10 min. Next, reactions containing 20 ng of PCR product and 4 pmol of the corresponding primer were prepared for Sanger sequencing on an ABI 360xl instrument (Applied Biosystems). Sequence traces were analyzed in SnapGene Viewer.

The rapid NAT2*4 acetylator variant was generated in a previous study\(^1\) by transfection of a pCMV6-Entry-NAT2 mammalian expression vector containing a Myc-tagged NAT2 open reading frame. To obtain a rapid acetylator phenotype, site-directed mutagenesis of rs1799930 (A590G) was performed using the QuickChange II Site-Directed Mutagenesis Kit (Agilent Technologies) in 50 μL reactions containing 1× reaction buffer, 125 ng of each primer, 0.2 mM dNTPs and 20 ng of dsDNA template. Primers used for site-directed mutagenesis included forward 5′-GAAGAGGTGGAAGGTGAGAAATATTTTTATATTTATTTTCC-3′ and reverse 5′-CCAGGAAATCTTTATATTTTCAGCACTTCTCACACTTCTC-3′, and were designed using the QuickChange algorithm (Agilent Technologies). Transfection of RKO cells was performed using Lipofectamine 2000 DNA Transfection Reagent (Invitrogen). The resulting stable clones were expanded under G418 selection (1 mg/mL) and confirmed to encode the wild-type NAT2 sequence by Sanger sequencing using primers forward 5′-GATCCCGTACCGAGAGGAT-3′ and reverse 5′-TGGTGCCAGACCTCTCCTCTC-3′.

**RT-qPCR analysis.** Direct cDNA extractions were performed from cell lysates using the TaqMan Gene Expression Cells-to-C\(_T\) Kit (Thermo Fisher Scientific). Overexpression of NAT2*5, NAT2*7 and NAT2*14 transcripts was detected by RT-qPCR using TaqMan probes against NAT2 (Hs01060665_g1) and the reference gene ACTB (Hs00156665_g1). Clones with similar levels of NAT2 expression were chosen for downstream analyses.

**Western blot.** Pellets from 2×10\(^6\) cells were lysed by addition of RIPA buffer (Thermo Scientific). Protein concentration was determined by the Novex BCA assay (Life Technologies) and 50 μg of sample were loaded and separated in a 4–12% SDS-PAGE gel (Life Technologies) at 180 V for 1 h. Sample transfer was performed at 20 V for 8 min using nitrocellulose iBlot Transfer Stacks (Thermo Scientific), which was later blocked with 5% BSA and probed overnight at 4 °C with rabbit Myc-tag (71D10, Cell Signaling Technology) and mouse β-actin (Clone AC-15, Sigma) primary antibodies. After incubation with rabbit and mouse secondary antibodies (31,460 and 31,430, Thermo Scientific), proteins were visualized by addition of SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific) in an ImageQuant LAS 4000 imaging system (GE Healthcare Life Sciences). Immunoblots were quantified in ImageJ and protein expression was quantified relative to β-actin loading control. Unprocessed immunoblot scans are provided in Supplementary Fig. 4.

**Determination of cell growth rate.** Cells were plated in six replicate wells of a 96-well plate at a density of 3000 cells per well. After 24 h, all wells were imaged in real time using the IncuCyte ZOOM live cell analysis system (Essen BioScience) and cell confluence was determined every 12 h for a period of 7 days.

**Quantification of NAT2 catalytic activity towards APA.** Cells were plated at a density of 18,000 cells per well in a 96-well plate. The next day, different concentrations of the substrate 6-(4-aminophenyl)-N-(3,4,5-trimethoxyphenyl)pyrazin-2-amine (APA) were added to the cells and the reaction was quenched after 30 min by addition of 99.8% MeOH. N-acetyl APA (NAPA) formation was detected by LC–MS/MS on a XEVO TQ (Waters) instrument coupled to an Acquity UPLC (Waters) using a HSS T3 column (1.7 μm, 2×50 mm). The mobile phases consisted of (A) 0.05% heptfluorobutyric acid and propionic acid, and (B) 0.05% heptfluorobutyric acid and propionic acid in acetonitrile. The m/z transitions 353 > 323 and 395 > 143 were monitored for APA and NAPA respectively.

**Cell viability assay.** Cells were seeded at a density of 8000 cells per well in a 96-well plate. The next day, medium containing different concentrations of APA was added. After 72 h, cell viability was determined in an MTT assay by addition of resazurin (Sigma-Aldrich) followed by fluorescence readouts at 590 nm in a Victor\(^\text{\textregistered}\) 1420 microplate reader (Perkin Elmer Wallac).

**NAT2 haplotype resolution by multiplexed single molecule real-time (SMRT) sequencing.** Genomic DNA was isolated from the human cancer cell lines RKO, DLD-1, VaCo-703 and HepG2 using the NucleoSpin Kit (Macherey–Nagel) according to the manufacturer's protocol. The exon 2 of NAT2 was amplified by PCR with the forward primer 5′-CAGCGAGGAAATCAATTGCTA-3′ and the reverse primer 5′-CGAGGCAATTGCTACCT-3′. Each reaction contained 1× Phusion HF Buffer (Thermo Scientific), 200 μM dNTPs, 0.5 μM forward and reverse primers, 0.02 U/μL Phusion Hot Start II High-Fidelity DNA Polymerase (Thermo Fisher Scientific) and 20 ng of genomic DNA. The PCR was performed in a 2720 Thermal Cycler (Applied Biosystems) following the touch-down protocol with 1 min of initial denaturation at 98 °C, 3 cycles of 98 °C for 30 s, 70 °C for 30 s, 72 °C for 2 min, 3 cycles of 98 °C for 30 s, 68 °C for 30 s, 72 °C for 2 min, 3 cycles of 98 °C for 30 s, 65 °C for 30 s, 72 °C for 2 min, 25 cycles of 98 °C for 30 s, 64 °C for 30 s, 72 °C for 2 min and 10 min of final elongation at 72 °C. Unprocessed PCR products were amplified using the FastStart DNA Polymerase (Roche), 0.5 μM forward and reverse primers, 0.02 U/μL Phusion Hot Start II High-Fidelity DNA Polymerase (Thermo Fisher Scientific) and 20 ng of genomic DNA. The PCR was performed in a 2720 Thermal Cycler (Applied Biosystems) following the touch-down protocol with 1 min of initial denaturation at 98 °C, 3 cycles of 98 °C for 30 s, 70 °C for 30 s, 72 °C for 2 min, 3 cycles of 98 °C for 30 s, 68 °C for 30 s, 72 °C for 2 min, 3 cycles of 98 °C for 30 s, 65 °C for 30 s, 72 °C for 2 min, 25 cycles of 98 °C for 30 s, 64 °C for 30 s, 72 °C for 2 min and 10 min of final elongation at 72 °C. Unprocessed PCR products were analyzed in SnapGene Viewer.
Estimation of NAT2 allelic frequencies in the 1000 Genomes Project dataset. The full chromosome 8 dataset for 2054 individuals from 1000 Genomes Project Phase 3 (Release 20,150,220) was downloaded from [ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/]. The genomic variation in the coding part of NAT2 was extracted in a form of phased alleles for each individual. The NAT2 allele definitions were taken from\(^{12}\) and matched to the variation at the rs200893121, rs22466456, rs45477599, rs14928360, rs1801279, rs1041983, rs1801280, rs144176822, rs1799930, rs1799931, rs149460636, rs1208, rs56393504 and rs1799931 positions in the alleles from the 1000 Genomes Project to identify the allele group and the specific NAT2 alleles present in each individual.

Whole genome sequencing of a Swedish cohort of colorectal cancers and patient-matched normal samples. Tumor and normal tissue samples were initially sectioned from a cohort of 173 stage I-III colorectal cancer patients. During this process, two patients were removed from the study cohort due to mismatches found between their tumor and corresponding normal samples. DNA was extracted from each sample in a Freedom EVO robot (Tecan) using magnetic nanoparticles. To discard tumors with microsatellite instability (MSI), PCR-based MSI detection was performed with the MSI Analysis System Version 1.2 (Promega), where the insertion or deletion of the repeating units NR-21, BAT-26, BAT-25, NR-24, MONO-27, Penta D and Penta C was evaluated. Fragments were sequenced in a 96-capillary 3730xl DNA Analyzer (Thermo Fisher Scientific) and MSI panels were analyzed using the GeneMapper software (Thermo Fisher Scientific). We discarded 24 MSI colorectal tumors, and proceeded with the analysis of tumor cell content in the remaining 147 samples. We identified 72 patients with tumors containing >40% of tumor cell content and discarded 8 patients who had previously received chemotherapy or radiotherapy. We additionally removed samples from 7 patients for which not enough DNA was available for downstream analyses. These selection criteria identified 56 patients with tumors and matched normal samples suitable for whole genome sequencing. Sequencing libraries were prepared in duplicates from 100 ng of DNA by using the TruSeq Nano DNA sample preparation kit (Illumina), targeting an insert size of 350 bp. Sequencing was performed in a HiSeqX System (illumina) with a paired-end 150 bp read length. The library preparation and sequencing were performed at the SNP&SEQ Technology Platform (ScilifeLab, Sweden). Tumor and normal samples were sequenced at a 90× read depth. The variant bases in positions corresponding to the SNPs rs1801279, rs1041983, rs1801280, rs1799929, rs1799930, rs144176822, rs1799931, rs1208, rs1799931, rs2552, rs4646247, rs971473, rs45547533, rs721398 and rs721399 were called separately for positions corresponding to the SNPs rs1801279, rs1041983, rs1801280, rs1799929, rs1799930, rs45607939, rs149460636, rs1208, rs56393504 and rs1799931 positions in the alleles from the 1000 Genomes Project to identify the allele group and the specific NAT2 alleles present in each individual.

Genotyping of a Finnish colorectal cancer patient cohort by SNP array. We derived 1611 cases with colorectal adenocarcinoma from the ongoing Finnish CRC collection (colorectal tissue or blood)\(^{31,32}\). The tumor and respective normal DNA samples were genotyped with an Infinium Omni1.2–8 (Illumina Inc.) array at the Estonian Genome Center. The B-Allele Frequencies and Log-R ratios for the polymorphisms rs45529434, rs7832071, rs1801279, rs1041983, rs1801280, rs1799929, rs144176822, rs1799930, rs45607939, rs149460636, rs1208, rs1799931, rs2552, rs4646247, rs971473, rs45547533, rs721398 and rs721399 were extracted with illumina Genome Studio software. The NAT2 haplotypes of 1511 patients with informative calls at the allele-classifying positions rs1801279, rs1041983, rs1801280, rs1799929, rs144176822, rs1799930, rs1208, rs1799931, rs2552, rs4646247, rs971473, rs45547533, rs721398 and rs721399 were called separately for the normal and tumor samples. The NAT2 alleles were imputed from the genotype data. The LOH was estimated as allelic imbalance in one or more informative positions, where there was an observed ≥10% shift of the number of sequencing reads supporting each allele.

Multiplexed high throughput sequencing of colorectal cancer patients samples. DNA isolated from 74 fresh frozen tumor and patient matched normal tissues was obtained from CRC patients with stage
II-IV disease. Extraction was performed on a liquid handling workstation Tecan Evo 150 MCA LiHa RoMa as previously described. The second NAT2 exon of each sample was amplified by PCR following the aforementioned protocol, however the primers contained additional sample-unique barcode sequence to allow amplification identification. The barcode sequences were those recommended by Pacific biosciences platform and the HPLC-purified primers were obtained from Sigma-Aldrich (Supplementary Table 4). Barcoded PCR products were pooled equimolarly based on the DNA concentration measurement by Qubit BR fluorometric assay (ThermoFisher). Following purification on a DNA-binding column (GeneJET Gel Extraction Kit), 2 pools of normal samples and 3 pools of tumor samples, each containing 2 µg of DNA were sequenced according to the manufacturers’ instructions using the P6-C4 chemistry in 5 separate SMRT cells using a PacBio RS II system at the National Genomics Infrastructure (NGI) of SciLifeLab, Uppsala.

Received: 3 April 2020; Accepted: 18 December 2020
Published online: 31 December 2020

References
1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-386 (2015).
2. Patel, D. K. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 28, 315-415 (2008).
3. Lungay-Vachet, V. & Tournagand, C. Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists. Targeted Oncol. 10, 199–213 (2015).
4. Muller, F. L. et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488, 337–342. https://doi.org/10.1038/nature11531 (2012).
5. Kryukov, G. V. et al. MTA2 deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science (New York, N.Y.) 351, 1214–1218. https://doi.org/10.1126/science.aad5214 (2016).
6. Mavrikas, K. J. et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science (New York, N.Y.) 351, 1208–1213. https://doi.org/10.1126/science.aad5944 (2016).
7. Dey, P. et al. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature 542, 119–123. https://doi.org/10.1038/nature21052 (2017).
8. Paolella, B. R. et al. Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. eLife 6, https://doi.org/10.7554/eLife.23268 (2017).
9. Nijhawan, D. et al. Cancer vulnerabilities unveiled by genomic loss. Cell 150, 842–854. https://doi.org/10.1016/j.cell.2012.07.023 (2012).
10. Liu, Y. et al. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature 520, 697–701. https://doi.org/10.1038/nature14118 (2015).
11. Rendo, V. et al. Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy. Nat. Commun. 11, 1308. https://doi.org/10.1038/s41467-020-15111-4 (2020).
12. Boukouvala, S. Human NAT2 alleles. http://nat.mbg.duth.gr/Human%20NAT2%20alleles_2013.htm (2016).
13. HPA. NAT2 in human protein atlas. https://www.proteinatlas.org/ENSG00000156006-NAT2-tissue (2017).
14. Windmill, K. F. et al. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol. Sci. Off. J. Soc. Toxicol. 54, 19–29 (2000).
15. Sabbagh, A. et al. Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet. 9, 21 (2008).
16. Grant, D. M. et al. Human acetyltransferase polymorphisms. Mutat. Res. 376, 61–70 (1997).
17. Heim, D. W. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 506–507, 65–77 (2002).
18. Sabbagh, A. & Darlu, P. Inferring haplotypes at the NAT2 locus: the computational approach. BMC Genet. 6, 30 (2005).
19. Snyder, M. W., Adey, A., Kitzman, J. O. & Shendure, J. Haplotype-resolved genome sequencing: experimental methods and applications. Nat. Rev. Genet. 16, 344–358 (2015).
20. Buermans, H. P. J. et al. Flexible and scalable full-length CYP2D6 long amplicon PacBio sequencing. Hum. Mutat. 38, 310–316 (2017).
21. Qiao, W. et al. Long-read single molecule real-time full gene sequencing of cytochrome P450-2D6. Hum. Mutat. 37, 315–323 (2016).
22. Genomes Project Consortium. A global reference for human genetic variation. Nature 526, 68–74 (2015).
23. Mortens, F., Johansson, B., Hogland, M. & Mitelman, F. Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Can. Res. 57, 2765–2780 (1997).
24. Pal, K. et al. Contribution of allelic imbalance to colorectal cancer. Nat. Commun. 9, 3664. https://doi.org/10.1038/s41467-018-06132-1 (2018).
25. Lengauer, C., Kinzler, K. W. & Vogelstein, B. Genetic instability in colorectal cancers. Nature 386, 623–627 (1997).
26. Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability—an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11, 220–228 (2010).
27. Heim, D. W. & Doll, M. A. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics 13, 31–41 (2012).
28. Hubbard, A. L. et al. N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 5p deletions. Gut 41, 229–234 (1997).
29. Sim, E., Abhammad, A. & Ryan, A. Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery. Br. J. Pharmacol. 171, 2705–2725. https://doi.org/10.1111/bph.12598 (2014).
30. Aaltenon, L. A. et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N. Engl. J. Med. 338, 1481–1487 (1998).
31. Mathot, L., Wallin, M. & Sjoblom, T. Automated serial extraction of DNA and RNA from biobanked tissue specimens. BMC Biotechnol. 13, 66. https://doi.org/10.1186/1472-6750-13-66 (2013).
Acknowledgements
This study was supported by grants to T.S. from the Swedish Cancer Foundation (2018/772), the Swedish Research Council (2016-01890), by the Swedish Society for Medical Research through a scholarship to I.S. and grants from the Jane and Aatos Erkko Foundation, Academy of Finland (Finnish Center of Excellence Program 2012–2017, 250345 and 2018–2025, 312041) to L.A. The authors declare no competing interest. Sequencing was performed by the SNP&SEQ Technology Platform in Uppsala. The facility is part of the National Genomics Infrastructure (NGI) Sweden and Science for Life Laboratory. The SNP&SEQ Platform is also supported by the Swedish Research Council and the Knut and Alice Wallenberg Foundation. The authors would like to acknowledge support of the National Genomics Infrastructure (NGI)/Uppsala Genome Center and UPPMAX for providing assistance in massive parallel sequencing and computational infrastructure. Work performed at NGI/Uppsala Genome Center has been funded by RFI/VR and Science for Life Laboratory, Sweden.

Authors’ contributions
T.S. designed the study. V.L. provided WGS data from the Swedish cohort. L.A. and K.P. provided array data from the Finnish cohort. I.S. performed the LOH analyses in the studied cohorts. V.R. and S.K. created, validated and analyzed cell models. R.S. and V.R. designed and performed in vitro biochemical validations experiments. N.R. conducted SMRT sequencing experiments in cell lines and patient samples. I.S. designed and analyzed SMRT sequencing data. T.S., V.R. and I.S. wrote the manuscript.

Funding
Open Access funding provided by Uppsala University.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-020-80288-z.

Correspondence and requests for materials should be addressed to T.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020